Bionor Pharma’s Phase II Vacc-4x Data Published in The Lancet Infectious Diseases

Therapeutic HIV Vaccine, Vacc-4x, Reduced Viral Load in HIV Patients Compared to Placebo in Largest Randomized, Placebo-controlled Study of its Kind in Recent History, Published in Lancet Infectious Diseases To access the article click here. For comment on the Vacc-4x trial and therapeutic vaccines research published in the Lancet Infectious Diseases click here. (Oslo, Norway, 11 February …

Read more

Potential Biomarker for Reduction of Viral Load Identified for Vacc-4x

Exploratory, ad hoc, subset analysis of previous large Vacc-4x Phase II study identifies patients more likely to respond to Vacc-4x (“Responders”) (Oslo, Norway, 4 February 2014)  Bionor Pharma ASA (OSE: BIONOR) announces that further analysis of the large Vacc-4x Phase II trial, completed in 2010, identified anti-C5 antibodies as potential biomarker for the Company’s lead …

Read more